Zobrazeno 1 - 10
of 545
pro vyhledávání: ''
Autor:
Tom Wei-Wu Chen, Herbert H. Loong, Sze Huey Tan, Alex K.C. Leung, Richard Quek, Chih Chi Chang, Angela Pang, Myo Myint Maw, Takeshi Hirose, Makoto Endo, Akira Kawai, Mark E. Puhaindran, Virote Sriuranpong, Siyamol Mingmalairak, Mohamad Farid, Jeffrey C.H. Chan, Wei Lin Goh, Roger K.C. Ngan
Publikováno v:
Cancer Science
Angiosarcoma (AS) is a rare disease with a dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, and metastatic disease remain elusive. The Asian Sarcoma Consortium is an internati
Autor:
Paul M. Barr, Hongli Li, Brad S. Kahl, Jerome D. Winegarden, Louis S. Constine, Lode J. Swinnen, Michael LeBlanc, Jonathan W. Friedberg, Joo Y. Song, Thomas P. Miller, Thomas J. Fitzgerald, John P. Leonard, Richard I. Fisher, Steven I. Park, Daniel O. Persky, Sonali M. Smith, Deborah M. Stephens, Lisa M. Rimsza, Nancy L. Bartlett
Publikováno v:
J Clin Oncol
PURPOSE Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The pref
Autor:
Masatoshi Matsuo, Tatsuro Jo, Kuniko Abe, Jun Taguchi, Hiroo Tominaga, Ritsuko Kubota-Koketsu, Yohei Kaneko, Shizuka Hayashi, Kazuto Shigematsu, Takahiro Sakai, Kaori Matsuzaka, Haruna Shioya
Publikováno v:
Anticancer Research. 40:5237-5243
Background/aim Adult T-cell leukemia/lymphoma (ATLL) is a relatively refractory CD4-positive peripheral T-cell lymphoma. VCAP-AMP-VECP (mLSG15) is one of the standard chemotherapeutic regimens for patients with aggressive ATLL. Mogamulizumab (moga),
Autor:
Ghassan K. Abou-Alfa, Eileen M. O'Reilly, Jinru Shia, Richard K. G. Do, Jennifer Ma, Joanne F. Chou, Marinela Capanu, Imane El Dika, Anna D. Hrabovsky, James J. Harding, Michele Ly, Brittanie M Millang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 20, Pp 7453-7459 (2020)
Cancer Medicine, Vol 9, Iss 20, Pp 7453-7459 (2020)
Background Patients with advanced hepatocellular carcinoma (HCC) who received second line sorafenib plus doxorubicin following disease progression on sorafenib were shown retrospectively to have improved progression free survival (PFS) and overall su
Autor:
Clémentine Sarkozy, Benjamin Suttle, Lionel Karlin, Romain Dubois, Gilles Salles, Sydney Dubois, Fabrice Jardin, Peggy Cullières-Dartigues, Steven Le Gouill, Hervé Tilly, Vincent Ribrag, Franck Morschhauser, Jean-Marie Michot, Jean-Michel Picquenot, Thierry Jo Molina, Charles Herbaux
Publikováno v:
Clinical Cancer Research. 26:3145-3153
Purpose: The histone-methyl transferase EZH2, catalytic subunit of the PRC2 complex involved in transcriptional regulation, is mutated in approximately 25% of germinal center B-cell lymphomas. Aberrant proliferative dependency on EZH2 activity can be
Autor:
Damien M. Cronier, Seth M. Pollack, Arun S. Singh, Gary Mo, Ashwin Shahir, Daniel A. Rushing, Mark Agulnik, Victor M. Villalobos, Brian A. Van Tine, Rodney Decker, Wei Zhang, Rhian McNaughton
Publikováno v:
Cancer Medicine, Vol 9, Iss 3, Pp 882-893 (2020)
Cancer Medicine
Cancer Medicine
Background Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin a
Autor:
K. Niraimathi, Channappa N Patil, Satish Kumar Anumula, Prasad Gunari, Karthik S Udupa, Neelesh Reddy, S. Ganapathi Raman, Shashidhar V. Karpurmath, Murugesan Janarthinakani, Parameswaran Anoop, Manjunath Nandennavar, Arun Seshachalam, Bharath Rangarajan, Krishnakumar Rathnam, Sirigeri Prabhakar Roopa, Basawantrao Malipatil, Krishna Prasad, Krishna Reddy Golamari, Madhav Danthala, Hemant Deepak Shewade
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-13 (2019)
Journal of Global Oncology
Journal of Global Oncology
PURPOSE Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) improves overall survival (OS) in patients with Hodgkin lymphoma (HL) relative to ABVD (doxorubicin, bleomycin, vinblastine, an
Autor:
Rohtesh S. Mehta, Elisabet E. Manasanch, Lei Feng, Chutima Kunacheewa, Sairah Ahmed, Donna M. Weber, Robert Z. Orlowski, Krina K. Patel, Samer Tabchi, Rajit Nair, Sheeba K. Thomas, Behrang Amini, Hans C. Lee, M.H. Qazilbash, Raymond Alexanian, Qaiser Bashir
Publikováno v:
Clin Lymphoma Myeloma Leuk
Background Multiple myeloma (MM) usually follows a clinical course leading to refractoriness and limited treatment options in advanced stages, which might need bridge therapies to either autologous stem cell transplantation or novel therapies. We rep
Autor:
Ravi Vij, Mark A. Fiala, Mark A. Schroeder, Savina Jaeger, Keith Stockerl-Goldstein, Armin Ghobadi, Tanya M. Wildes, Kathryn Shea, Eric Huselton, Sae Rin Jean, Michael H. Cardone
Publikováno v:
Clin Cancer Res
Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM). Carfilzomib, a second-generation proteasome inhibitor, has clinical efficacy even among bortezomi
Publikováno v:
Leukemia & Lymphoma. 60:2909-2916
The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than th